Chiara Riganti graduated in Medicine at University of Torino, Italy in 2002, and obtained the Specialization in Clinical Biochemistry at University of Torino, Italy, in 2006. She worked as visiting scientist at the Institute Cochine, INSERM, Paris, in 2010, and visiting professor at the Weizmann Institute of Science, Rehovot, Israel in 2011 and 2013. She is currently associate professor of biochemistry at the Oncological Pharmacology Unit, University of Torino. Her research is focused on multi-target drugs able to induce chemo- and immune-sensitization. She awarded the “SIB medal” for young investigators (2005); the “AICC prize for senior investigators” (2011); the “Outstanding Achievements in Oncology Award” at 22nd World Congress on Advances in Oncology in 2017. She co-authored more than 180 papers in international peer-review journals (H-index: 40) and filed 5 patents. She is member of the Editorial Board of Frontiers in Pharmacology, Frontiers in Oncology; Cancer Drug Resistance.
Drug Discovery and Development
Drug Discovery and Development
All accepted abstracts will be published in respective Allied Academies Journals.
Abstracts will be provided with Digital Object Identifier by
